Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: The combined systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) (SII-PNI score) serves as a prognostic predictor in various malignancies. This study evaluates the prognostic value of the SII-PNI score in patients with unresectable hepatocellular carcinoma (uHCC) treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors (triple therapy).
Patients And Methods: This retrospective multicenter study included patients with uHCC treated with triple therapy from eight hospitals. The optimal cut-off values for SII and PNI were determined using X-tile. The SII-PNI score was categorized as follows: score of 0, low SII (≤cut-off value) and high PNI (>cut-off value); score of 1, either high SII-high PNI or low SII-low PNI; score of 2, high SII and low PNI. Survival curves were estimated and compared using the Kaplan-Meier method with the Log rank test.
Results: A total of 290 patients were included. The optimal cut-off values were 525.9 for SII and 44.0 for PNI. Patients were classified as SII-PNI score of 0 (n = 105), score of 1 (n = 124), and score of 2 (n = 61). Lower SII-PNI score was associated with better median overall survival (score of 0: not reached vs score of 1: 28.0 months vs score of 2: 19.7 months; < 0.001). Similarly, the median progression-free survival for SII-PNI scores of 0, 1, and 2 was 25.5, 16.6, and 12.9 months, respectively ( < 0.001). Lower SII-PNI score also indicated better objective response rate ( = 0.007) and disease control rate ( = 0.003). The SII-PNI score was identified as an independent predictor of overall survival and progression-free survival in multivariate COX regression analysis.
Conclusion: The SII-PNI score is associated with survival and tumor response in patients with uHCC treated with triple therapy. This score aids in optimizing clinical decision-making for uHCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171012 | PMC |
| http://dx.doi.org/10.2147/JIR.S520339 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic value of immune-inflammation and nutritional indices in advanced hepatocellular carcinoma patients receiving immunotherapy with compound Kushen injection.
World J Gastrointest Oncol
July 2025
The First Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China.
Background: Advanced hepatocellular carcinoma (HCC) with ascites (AS) lacks reliable biomarkers for predicting treatment outcomes. The combined prognostic value of the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) remains underexplored for novel therapies.
Aim: To evaluate the clinical efficacy of combining intraperitoneal compound Kushen injection (CKI) with immunotherapy in patients with advanced HCC using a scoring system that combines SII and PNI.
Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors.
J Inflamm Res
June 2025
Shengli Clinical Medical College of Fujian Medical University, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, People's Republic of China.
Purpose: The combined systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) (SII-PNI score) serves as a prognostic predictor in various malignancies. This study evaluates the prognostic value of the SII-PNI score in patients with unresectable hepatocellular carcinoma (uHCC) treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors (triple therapy).
Patients And Methods: This retrospective multicenter study included patients with uHCC treated with triple therapy from eight hospitals.
Combined Systemic Immune-Inflammation Index-Prognostic Nutritional Index Score in Evaluating the Prognosis of Patients with Severe Community-Acquired Pneumonia.
J Inflamm Res
May 2025
Department of Respiratory and Critical Care Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Background: While both the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) have demonstrated prognostic value in various diseases, the clinical utility of their combined score (SII-PNI) for predicting outcomes in patients with severe community-acquired pneumonia (SCAP) remains incompletely understood. The aim of this study is to explore the predictive value of SII-PNI score in patients with SCAP.
Methods: We conducted a retrospective analysis of the clinical data of 138 patients diagnosed with SCAP.
Association of Systemic Inflammatory Response Index and Prognostic Nutritional Index Scores with Sarcopenia in Patients with Metastatic Gastric Cancer.
Medicina (Kaunas)
April 2025
Department of Radiology, Dokuz Eylül University, Izmir 35340, Turkey.
Sarcopenia is frequently observed in cancer patients and is associated with short survival. In this study, the aim was to research the sarcopenia risk factors, the correlation of sarcopenia with inflammatory biomarkers, and the prognostic significance of sarcopenia and inflammation markers in patients with metastatic gastric cancer. : The study included 177 patients diagnosed with metastatic gastric cancer attending Dokuz Eylül University Faculty of Medicine (DEUFM) Medical Oncology clinic from 2016 to 2022.
View Article and Find Full Text PDFCan pretreatment lactate dehydrogenase to albumin ratio predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients?
J Med Biochem
March 2025
Gazi University, School of Medicine, Department of Medical Oncology, Ankara, Turkey.
Background: This study aims to evaluate the predictive significance of platelet lymphocyte ratio (PLR), neutrophillymphocyte ratio (NLR), lymphocyte monocyte ratio (LMR), systemic immune-inflammation (SII), prognostic nutritional index (PNI), haemoglobin, albumin, lymphocyte, and platelet (HALP) score and lactate dehydrogenase to albumin ratio (LAR) for pCR in breast cancer with neoadjuvant chemotherapy (NACT).
Methods: A total of 121 patients who received NACT between February 2012 and November 2021 were included. LAR, NLR, PLR, MLR, SII, PNI and HALP were calculated using formulas.